Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Reneo Pharmaceuticals (RPHM) News Today

Reneo Pharmaceuticals logo
Onkure Therapeutics Inc (OKUR)
Reneo Pharmaceuticals, Inc. stock logo
Nantahala Capital Management LLC Invests $846,000 in Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM)
Nantahala Capital Management LLC purchased a new stake in Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 547,804 shares of the company's stock, val
Reneo Pharmaceuticals, Inc. stock logo
Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Major Shareholder Braden Michael Leonard Purchases 29,600 Shares
Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM - Get Free Report) major shareholder Braden Michael Leonard bought 29,600 shares of Reneo Pharmaceuticals stock in a transaction on Tuesday, September 24th. The stock was acquired at an average price of $1.41 per share, for a total transaction of $41,736.00. Following the purchase, the insider now owns 3,388,649 shares of the company's stock, valued at $4,777,995.09. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Major shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.
Reneo Pharmaceuticals, Inc. stock logo
Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Receives Consensus Rating of "Reduce" from Analysts
Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM - Get Free Report) has been assigned a consensus recommendation of "Reduce" from the eight analysts that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and seven have assign
Reneo Pharmaceuticals, Inc. stock logo
Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Given Average Recommendation of "Reduce" by Analysts
Shares of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM - Get Free Report) have been given an average rating of "Reduce" by the eight ratings firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating and seven have issued a hold rating on the
Reneo Pharmaceuticals, Inc. stock logo
Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Given Consensus Rating of "Reduce" by Brokerages
Shares of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM - Get Free Report) have been given an average recommendation of "Reduce" by the eight brokerages that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and seven have given a hold r
Reneo Pharmaceuticals, Inc. stock logo
Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Short Interest Up 18.2% in May
Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM - Get Free Report) was the target of a significant increase in short interest in May. As of May 15th, there was short interest totalling 3,630,000 shares, an increase of 18.2% from the April 30th total of 3,070,000 shares. Approximately 16.7% of the shares of the stock are sold short. Based on an average daily volume of 265,100 shares, the short-interest ratio is currently 13.7 days.
Reneo Pharmaceuticals, Inc. stock logo
Highbridge Capital Management LLC Purchases Shares of 1,121,704 Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM)
Highbridge Capital Management LLC acquired a new stake in Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,121,704 shares of the company's stock, valued at a
Reneo Pharmaceuticals, Inc. stock logo
Insider Buying: Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Major Shareholder Acquires 414,281 Shares of Stock
Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM - Get Free Report) major shareholder Braden Michael Leonard purchased 414,281 shares of the company's stock in a transaction that occurred on Tuesday, May 14th. The stock was bought at an average price of $1.54 per share, for a total transaction of $637,992.74. Following the transaction, the insider now directly owns 2,672,194 shares in the company, valued at $4,115,178.76. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.
Reneo Pharmaceuticals, Inc. stock logo
Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Receives Average Rating of "Reduce" from Brokerages
Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM - Get Free Report) has been given an average rating of "Reduce" by the eight ratings firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and seven have assigned a hold rating to th
Reneo Pharmaceuticals, Inc. stock logo
Reneo Pharmaceuticals (NASDAQ:RPHM) Stock Rating Reaffirmed by HC Wainwright
HC Wainwright reiterated a "neutral" rating and issued a $1.50 price objective on shares of Reneo Pharmaceuticals in a report on Tuesday.
Reneo Pharmaceuticals, OnKure To Merge
Reneo Pharmaceuticals, Inc. stock logo
Q2 2024 EPS Estimates for Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Reduced by Analyst
Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM - Free Report) - Analysts at Leerink Partnrs dropped their Q2 2024 EPS estimates for shares of Reneo Pharmaceuticals in a report issued on Tuesday, May 7th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings of ($0.22)
Reneo Pharmaceuticals, Inc. stock logo
BML Capital Management LLC Makes New Investment in Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM)
BML Capital Management LLC bought a new position in Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,314,229 shares of the company's stock, valued at approximately
Reneo Pharmaceuticals Inc.
Reneo Pharmaceuticals, Inc. stock logo
Reneo Pharmaceuticals (NASDAQ:RPHM) Trading Up 0.6%
Reneo Pharmaceuticals (NASDAQ:RPHM) Trading Up 0.6%
Get Reneo Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RPHM and its competitors with MarketBeat's FREE daily newsletter.

We recommended Palantir in 2021, now we’re recommending this... (Ad)

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol

RPHM Media Mentions By Week

RPHM Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RPHM
News Sentiment

0.00

0.60

Average
Medical
News Sentiment

RPHM News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RPHM Articles
This Week

0

1

RPHM Articles
Average Week

Get Reneo Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RPHM and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:RPHM) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners